# Drug Recalls and Quality Withdrawals

> Drug recalls for NEET-PG Pharmacology: NSQ versus spurious drugs, CDSCO Class I-III timelines, DEG syrup tragedies and pharmacovigilance links.

- Canonical URL: https://prepelephant.com/topics/neet-pg/pharmacology/drug-recalls-quality-withdrawals
- Exam / course: NEET-PG · Subject: Pharmacology
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "Drug Recalls and Quality Withdrawals", PrepElephant, https://prepelephant.com/topics/neet-pg/pharmacology/drug-recalls-quality-withdrawals

## Direct answer

A batch of cough syrup fails laboratory testing — the machinery of drug recalls begins: the sample is declared not of standard quality (NSQ) or spurious by a Central or State Drugs Laboratory, the licence holder withdraws the batch from the market, and the risk level decides the clock. CDSCO recall guidelines (revised 2024) adopt a three-class system mirroring international practice — Class I for dangerous or defective products with serious health risk, completed within 24 hours (up to 72 at the outside); Class II within 10 days; Class III within 30 days — though the framework remains guideline-based, not a statutory recall law under the Drugs and Cosmetics Act, 1940. Market withdrawal for safety, distinct from batch recall, travels through pharmacovigilance — PvPI signal detection at IPC Ghaziabad leading to label changes, restrictions or licence suspension.

## What you must remember

- **Terminology that earns marks:** an NSQ drug fails quality standards (wrong assay, dissolution, contamination); a spurious drug is deliberately misrepresented — fake identity, copied labels, or sold under another's name; an adulterated drug contains harmful substitution.
- **Recall classes and clocks:** Class I (serious risk — wrong ingredient, contaminated injectables): withdraw within 24 hours and notify authorities within 24 hours of awareness; Class II (temporary or medically reversible harm): up to 10 days; Class III (unlikely to cause harm — minor label defects): up to 30 days.
- **Who acts:** drug inspectors of State and Central authorities sample and seize; the Central Drugs Laboratory (Kolkata) is the appellate analyst; manufacturers bear primary recall responsibility — the federal split (most manufacture licensed by states) is the structural weakness examiners quote.
- **Quality-tragedy anchors:** diethylene glycol (DEG) and ethylene glycol contamination of cough syrups — the Gambia and Uzbekistan deaths of 2022 traced to Indian-manufactured syrups — drive excipient identity testing; DEG is metabolised to oxalic acid and causes acute kidney injury with cranial neuropathy.
- **Recall versus withdrawal versus suspension:** batch recall (one defective batch), market withdrawal (minor violation), safety withdrawal of the molecule (phenformin, rofecoxib, cisapride in India's own history), and licence suspension (regulatory punishment).
- **Vigilance linkage:** unexpected therapeutic failure or batch-clustered reactions should be reported to PvPI as suspected quality problems.
- **Scale of the problem:** recent CDSCO surveillance declares double-digit to low-hundreds NSQ samples monthly with single-digit spurious detections — on the order of 2-3 per cent NSQ of tested samples in recent years.

## A worked recall walkthrough

A state drug inspector's routine sample of a paediatric paracetamol syrup returns "assay 62 per cent of label claim; fails dissolution." The declaration is NSQ, classified Class II — subtherapeutic analgesia in a child, temporary and reversible harm. The manufacturer halts distribution, retrieves the batch through stockists, publishes recall notices, and files effectiveness checks; the state licensing authority verifies, and CDSCO's monthly NSQ list carries the batch number publicly. Had the failure been DEG contamination, the classification jumps to Class I with a 24-hour clock — and probable criminal proceedings if misrepresentation is established.

The clinician's role: report the suspected batch to PvPI, retain the sample, and document the batch number in the case notes — pharmacovigilance and quality surveillance converge at the bedside.

## How the exam frames it

Two stems dominate. The definitional one: distinguish NSQ from spurious from adulterated — the intent element separating spurious from merely substandard. The systems one: name the recall classes with their timelines (24 hours, 10 days, 30 days) and the CDSCO guideline basis, noting for the viva that India still lacks a statutory recall law, the framework operating through guidelines and the D&C Act's general powers. The toxicology crossover brings DEG: oxalic-acid metabolism, renal tubular and cranial-nerve injury, and the preventive pharmacopeial identity tests for glycols. Programme-level questions link recalls to PvPI reporting and the consumer-facing CDSCO NSQ notices.

## Frequently asked questions

### What is the difference between an NSQ and a spurious drug?

A not-of-standard-quality drug genuinely originates from its manufacturer but fails quality parameters (assay, dissolution, contamination), while a spurious drug is misrepresented — imitation identity, false labelling, or another's name — carrying far harsher penalties under the Drugs and Cosmetics Act.

### What are the three recall classes and their timelines in India?

Class I (serious health risk) completes withdrawal within 24 hours, extendable to 72; Class II (temporary or reversible harm) within 10 days; Class III (unlikely to cause harm) within 30 days.

### Why is diethylene glycol contamination of syrups lethal?

DEG is metabolised to oxalic and glycolic acids, producing acute tubular injury with anuric renal failure, metabolic acidosis and cranial neuropathy — deaths in Gambia and Uzbekistan in 2022 tightened excipient testing globally.

### How does a clinician contribute to drug recall systems?

Report suspected quality failures — therapeutic failure, batch-clustered adverse events — to PvPI with the batch number retained, feeding the signal machinery that triggers testing and recall.

### Does India have a statutory drug recall law?

Not a dedicated one; recalls operate under Drugs and Cosmetics Act powers plus CDSCO guidelines revised in 2024, and this guideline-based status is a recognised regulatory gap.